NICE will take responsibility for assessing the full value of medicines when new pricing arrangements are introduced in 2014 the Government announced today.
The Government confirmed the plans in its official response to the Health Select Committee’s report on the future role of NICE which has been published today. The move will give NICE a crucial role in the future value-based pricing arrangements for branded medicines. It will allow the body to build on its current drug evaluation processes by giving it broader scope to assess a medicine’s benefits and costs. The aim is to make sure that the price the NHS pays for new medicines is more closely linked to their value to NHS patients and society.